Am J Transplant, Volume 16, Suppl 3 Archives - Page 124 of 180 - ATC Abstracts

2016 American Transplant Congress
African-American Primary Renal Transplant Recipients Are at a Significantly Higher Risk to Develop De Novo DSA.
M. Everly,¹ L. Rebellato,² C. Haisch,² K. Briley,² P. Bolin,² S. Kendrick,³ C. Morgan,² A. Maldonado,⁴ A. Nguyen,¹ P. Terasaki.¹
¹Terasaki Foundation Laboratory, Los Angeles; ²East Carolina University, Greenville, NC; ³Eastern Nephrology Associates, Greenville, NC; ⁴Vidant Medical Center, Greenville, NC.
Recent studies have shown multiple risk factors for de novo DSA (dnDSA) development. One controversial risk factor is race. Studying a primarily African-American (AA) transplant…
2016 American Transplant Congress
Kidney Retransplantation Is Associated with Higher Mortality Risk Among HIV+ vs. HIV- Recipients.
B. Shelton,¹ S. Mehta,¹ D. Sawinski,² R. Reed,¹ P. MacLennan,¹ S. Gustafson,³ C. Durand,⁴ D. Segev,⁴ J. Locke.¹
¹School of Medicine, University of Alabama at Birmingham, Birmingham, AL; ²School of Medicine, University of Pennsylvania, Philadelphia, PA; ³Scientific Registry of Transplant Recipients, Minneapolis, MN; ⁴School of Medicine, Johns Hopkins University, Baltimore, MD.
Background: Excellent outcomes have been demonstrated in HIV+ kidney transplant (KT) recipients, yet no study has explored outcomes among HIV+ reKT recipients.Methods: 4,683 adult reKT…
2016 American Transplant Congress
Modification of DC Phenotype and Function via Targeted Porous Silicon Nanoparticles.
S. Stead,¹ S. McInnes,² S. Kireta,³ P. Rose,¹ D. Rojas-Canales,³ S. Jesudason,³ S. Grey,⁴ R. Carroll,³ N. Voelcker,² P. Coates.^1,3
¹School of Medicine, University of Adelaide, Adelaide, Australia; ²Future Industries Institute, University of South Australia, Adelaide, Australia; ³CNARTS, Royal Adelaide Hospital, Adealide, Australia; ⁴Transplantation Immunology, Garvan Institute of Medical Research, Sydney, Australia.
Aims: Dendritic cells (DC) are the most potent antigen-presenting cell and are fundamental in the establishment of transplant tolerance. Targeting DC via the DC-SIGN receptor…
2016 American Transplant Congress
Three-Year Graft Loss Risk in Kidney Transplants: Dynamic Patient Level Data Improve Predictive Efficacy.
T. Srinivas, J. Zhang, Z. Su, D. Taber, J. Marsden, K. Reilly, D. Northrup, J. Long, L. Lenert, W. Moran, P. Mauldin.
MUSC, Charleston, SC.
Background: Predictive models in kidney transplantation using national data (UNOS, SRTR) lack longitudinal patient level data, limiting accuracy. Adding patient level data capturing dynamic clinical…
2016 American Transplant Congress
Outcomes Associated with Carbapenem-Resistant Enterobacteriaceae Infection After Solid Organ Transplantation in a Multicenter Study.
S. Huprikar,¹ L. Casner,¹ L. Camera Pierrotti,² A. Nellore,³ R. Madan,⁴ J. Garcia-Diaz,⁵ S. Jacobs,⁶ D. Lee,⁷ W. Trindade Clemente,⁸ G. Alangaden,⁹ R. La Hoz,¹⁰ N. Theodoropoulos,¹¹ M. Miceli,¹² G. Santoro-Lopes,¹³ D. Banach,¹⁴ D. Simon,¹⁵ G. Patel.¹
¹Mount Sinai, New York; ²Univ of Sao Paulo, Sao Paulo, Brazil; ³UAB, Birmingham; ⁴Albert Einstein, Bronx; ⁵Oschner, New Orleans; ⁶Cornell, New York; ⁷Drexel, Philadelphia; ⁸Univ Federal de Minas Gerais, Belo Horizonte, Brazil; ⁹Henry Ford, Detroit; ¹⁰UT Southwestern, Dallas; ¹¹Ohio State, Columbus; ¹²U of Michigan, Ann Arbor; ¹³Federal Univ of Rio de Janeiro, Rio de Janeiro, Brazil; ¹⁴Yale, New Haven; ¹⁵Rush, Chicago.
BackgroundCarbapenem-resistant Enterobacteriaceae infection (CREI) is associated with poor outcomes in solid organ transplant (SOT) recipients but most reports are single center experiences.MethodsPatients who underwent SOT…
2016 American Transplant Congress
Incidence and Renal Consequences of Type 2 Diabetes Mellitus in Kidney Donors.
H. Ibrahim, A. Matas, D. Berglund, S. Reule, A. Kukla, N. Issa, R. Spong, R. Foley.
U of MN, Mpls.
Diabetes Mellitus (DM) continues to be the most common cause of kidney disease. The incidence of DM following kidney donation is unknown. Moreover, whether its…
2016 American Transplant Congress
Superior Waitlist and Equivalent Transplant Outcomes Among Hepatitis C RNA-Positive Patients Who Are Willing to Accept Hepatitis C Seropositive Kidneys.
J. Sageshima,¹ A. de Mattos,² C. Troppmann,¹ C. Santhanakrishnan,¹ J. McVicar,¹ B. Gallay,² M. Gandhi,² M. Alnimri,² R. Perez.¹
¹Surgery, University of California-Davis, Sacramento, CA; ²Internal Medicine, University of California-Davis, Sacramento, CA.
Background: kidney transplantation from hepatitis C seropositive (HCV+) donors may benefit hepatitis C RNA-positive (RNA+) candidates, but it is not clear how the acceptance/listing status…
2016 American Transplant Congress
99% and 100% CPRA Patients Since KAS: A Substantial Increase in Transplants with Strong Evidence of a Bolus Effect.
A. Kucheryavaya,¹ M. Aeder,² N. Turgeon,³ D. Klassen,¹ D. Stewart.¹
¹UNOS, Richmond, VA; ²Univ Hosp Case Med Ctr, Cleveland, OH; ³Emory Univ Hosp, Atlanta, GA.
Background: The Kidney Allocation System (KAS), implemented on 12/4/14, increased allocation priority for candidates with CPRA of 99-100%. Analyses performed on behalf of the OPTN…
2016 American Transplant Congress
Short Term Changes in HRQOL Following Kidney Transplantation.
I. Olorundare, H. Ying, M. McAdams-DeMarco, D. Segev.
JHU, Baltimore.
Health-Related Quality of Life (HRQOL) is a patient-centered outcome that measures the impact of a disease and its treatment. This is particularly relevant to those…
2016 American Transplant Congress
Everolimus Plus Reduced-Exposure Cyclosporin versus Mycophenolic Acid Plus Cyclosporin: Seven-Year Follow-Up of Australia and New Zealand Kidney Transplant Recipients in the A2309 Study.
S. Chadban,¹ H. Pilmore,² G. Russ,³ J. Kanellis,⁴ S. Campbell,⁵ P. O'Connell,⁶ W. Lim,⁷ M. Lutherborrow,⁸ N. Kurstjens,⁸ R. Walker.⁹
¹Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; ²Auckland Renal Transplant, Auckland City Hospital, Auckland, New Zealand; ³Central Northern Adelaide Ranel and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia; ⁴Renal Medicine, Monash Medical Centre, Melbourne, Australia; ⁵University of Queensland, Princess Alexandra Hospital, Queensland, Australia; ⁶Renal Medicine, Westmead Hospital, Sydney, Australia; ⁷WA Liver and Kidney Transplant Service, Sir Charles Gairdner Hospital, Perth, Australia; ⁸Novartis Pharmaceuticals, Sydney, Australia; ⁹Renal Medicine, Alfred Hospital, Melbourne, Australia.
A2309 was a 2-year, phase III randomized controlled trial evaluating the effect on graft and patient outcomes of three groups:1.5mg everolimus plus low exposure cyclosporine…